Prognostic Value of Tumor Markers, NSE, CA125 and SCC,  in Operable NSCLC Patients

Yu, Dangfan; Du, Ke; Liu, Taifeng; Chen, Guojun

doi:10.3390/ijms140611145

Cited by 67 publications

(72 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nowadays, a series of biomarkers have been recommended to diagnose and manage those patients with lung cancer, including CEA, NSE, CYFRA21-1 and SCCA (15,16). Since cancer biomarker discovery has started extensively with the progress of proteomic technology, many protein molecules have been indicated as potential cancer biomarkers (17).…”

Section: Discussionmentioning

confidence: 99%

Increased stathmin in serum as a potential tumor marker for lung adenocarcinoma

Biaoxue

Liu

Tian

et al. 2017

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Background: Stathmin has been found to be involved in malignant tumors; the aim of this study was to investigate the relationship between serum stathmin and clinico-pathological features of lung cancer. Methods: In three lung cancer cell lines, stathmin expression and its secretion level in the supernatant were examined by Western blot and enzyme-linked immunosorbent assay (ELISA). Expression of stathmin was examined by immunohistochemistry in 48 lung cancer tissues, and serum stathmin expression level was examined by ELISA in 96 patients with lung cancer and 82 normal individuals. Sensitivity and specificity of serum stathmin were determined by receiver operator characteristic curve (ROC). Results: In the three cell lines and their supernatant, stathmin levels were higher than those in 16 HBE cell line. Lung cancer tissues expressed higher level stathmin more frequently than normal lung tissue (P < 0.05). Serum stathmin level was significantly higher in the patients with lung cancer than in normal individuals (P < 0.001). Increased stathmin level in cancer tissue and serum were significantly associated with adenocarcinoma histology, lymph node metastasis and advanced stage. The threshold level of serum stathmin for distinguishing lung cancer from normal individuals was 1.86 ng/ml. The sensitivity and specificity were 93.7% and 91.5%, respectively. Conclusions: Measurement of serum stathmin level could be a potential biomarker for lung cancer, especically those of adenocarcinoma, with lymph node metastasis and at advanced clinical stages.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased stathmin in serum as a potential tumor marker for lung adenocarcinoma

Biaoxue

Liu

Tian

et al. 2017

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Clinical laboratory echnicians found that combined tumor markers has relatively higher sensitivity in daily work. Researchers found that combined detection had great value in the diagnosis, analysis of effect, recurrence detection and prognosis of cancer (Duffy et al, 2013;Li et al, 2013;Sisik et al, 2013;Wang et al, 2013;Yu et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Combined Detection of Serum Tumor Markers in Diagnosis of Patients with Ovarian Cancer

Bian¹,

Li²,

Kou³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: To explore the predictive value of tumor markers, including cancer antigen 72-4 (CA72-4), cancer antigen 15-3 (CA15-3) and cancer antigen 125 (CA125), in single or combined detection, for the diagnosis of ovarian cancer. Methods: 120 patients diagnosed with ovarian cancer from August 2011 to March 2013 and 80 patients diagnosed with benign ovarian tumors were enrolled in this test, along with 50 health examination women randomly selected from the database as controls. Serum levels of CA72-4, CA15-3 and CA125 in this study were determined by electrochemiluminescence (ECL). Results: Serum levels of CA72-4, CA15-3 and CA125 in ovarian cancer were higher than those in healthy group and benign group (P<0.01).The sensitivity of combined detection of those three tumor markers for diagnosis of ovarian cancer was obviously higher than with single detection with each marker (P<0.01). Conclusions: CA72-4, CA15-3 and CA125 could be a good combination in the diagnosis of ovarian cancer. Patients whose tumor markers continue to increase should be highly suspected of malignancy.

show abstract

“…Based on the univariate Cox regression analysis, we assigned the SIG12 score of the 12 genes as follows: SIG12 score = (0.324 × expression value of ADM) + (−0.379 × expression value of CYSLTR1) + (0.353 × expression value of DDIT4) + (−0.326 × expression value of DOCK8) + (0.29 × expression value of ENO2) + (−0.28 × expression value of FCER1A) + (−0.286 × expression value of IL17A) + (−0.328 × expression value of IZUMO4) + (−0.273 × expression value of MMP25) + (−0.362 × expression value of P2RY14) + (0.292 × expression value of RBP4) + (−0.299 × expression value of ZNF252P‐AS1). The known or putative functions and clinical relevance are described in Table .…”

Section: Resultsmentioning

confidence: 99%

A gene signature associated with prognosis and immune processes in head and neck squamous cell carcinoma

Bai

Zhang

et al. 2019

Head & Neck

View full text Add to dashboard Cite

Background Head and neck squamous cell carcinoma (HNSCC) has a poor prognosis that has not significantly improved in the past several decades. A prognostic‐related signature was needed. Methods The Cancer Genome Atlas and GSE41613 databases were downloaded as a training and validation set, respectively. We identified 12 genes that demonstrated progression and prognostic value, and then, a gene signature was constructed. Results This classification could reflect distinct characteristics, phenotypically and molecularly, among HNSCC tumors. It could stratify patients with significantly different survival rates (median survival: 2083 days vs 927 days; P = 3.85E‐08) in the training cohort and validation cohort (P = 0.007) and was significantly involved in immune/inflammatory response and tumor progression processes. Conclusions This bioinformatics‐based signature suggested the presence of two distinct populations of patients with HNSCC with distinguishable phenotypic characteristics and clinical outcomes and might provide insight for new types of immune therapy.

show abstract

Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients

Cited by 67 publications

References 33 publications

Increased stathmin in serum as a potential tumor marker for lung adenocarcinoma

Increased stathmin in serum as a potential tumor marker for lung adenocarcinoma

Clinical Significance of Combined Detection of Serum Tumor Markers in Diagnosis of Patients with Ovarian Cancer

A gene signature associated with prognosis and immune processes in head and neck squamous cell carcinoma

Contact Info

Product

Resources

About